Form 4: Amneal Pharmaceuticals Director Buchi J Kevin Reports Stock Transactions

Director Buchi J Kevin reports acquisition and disposal of Amneal Pharmaceuticals Class A Common Stock and Restricted Stock Units.

Summary

• On May 5, 2025, Director Buchi J Kevin executed transactions involving Amneal Pharmaceuticals' Class A Common Stock and Restricted Stock Units.
• The transactions included the acquisition of 40,258 shares of Class A Common Stock through the vesting of Restricted Stock Units.
• Following the reported transactions, Buchi J Kevin directly owns 40,258 shares of Class A Common Stock and indirectly owns 262,072 shares through a trust.
• Additionally, 34,819 Restricted Stock Units were acquired on May 6, 2025, which vest on the later of the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and the day immediately following the first anniversary of the date of grant.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard regulatory filing reporting stock transactions. There is no indication of positive or negative sentiment.

Positives

• The vesting of restricted stock units indicates a continued alignment of the director's interests with those of the shareholders.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the trading activities of key personnel.

Stakeholder Impact

• The transactions may provide stakeholders with insights into the director's confidence in the company's future prospects.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Director, Buchi J Kevin, Class A Common Stock, Restricted Stock Units, Beneficial Ownership, Form 4, SEC